Accueil > BIGG > Résultat de la recherche

    Résultats: 2

    COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). Last updated: 22 June 2022

    England. National Institute for Health and Care Excellence.
    This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VI...
    Vaccins contre la COVID-19/effets indésirables, Purpura thrombopénique idiopathique/complications, Thrombose/complications, SARS-CoV-2/effets des médicaments et des substances chimiques, Ad26COVS1/effets indésirables, Vaccin ChAdOx1 nCoV-19/effets indésirables, Vaccin BNT162/effets indésirables
    Texte intégral

    Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices: United States, December 2021

    Oliver, Sara E; Wallace, Megan; See, Isaac; Mbaeyi, Sarah; Godfrey, Monica; Hadler, Stephen C; Jatlaoui, Tara C; Twentyman, Evelyn; Hughes, Michelle M; Rao, Agam K; Fiore, Anthony; Su, John R; Broder, Karen R; Shimabukuro, Tom; Lale, Allison; Shay, David K; Markowitz, Lauri E; Wharton, Melinda; Bell, Beth P; Brooks, Oliver; McNally, Veronica; Lee, Grace M; Talbot, H. Keipp; Daley, Matthew F.
    MMWR recomm. rep; 71 (3), 2022
    On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
    Thrombose/complications, Ad26COVS1/effets indésirables, Programmes de vaccination/normes, COVID-19/prévention et contrôle, Syndrome de Guillain-Barré/complications
    Texte intégral